Fewer study participants needed to demonstrate superior antidepressant efficacy when using the Hamilton melancholia subscale (HAM-D6) as outcome measure

Journal of Affective Disorders

Volumn 190, Issue , 2016, Pages 842-845

  østergaard, Søren Dinesen ^a,b   Bech, Per ^c   Miskowiak, Kamilla Woznica ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b H LUNDBECK A S   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d Rigshospitalet   (Denmark)

Author keywords

Depressive disorder; Erythropoeitin; Psychiatric status rating scales; Treatment resistant

Indexed keywords

ERYTHROPOIETIN; PLACEBO; ANTIDEPRESSANT AGENT;

17 ITEM HAMILTON MELANCHOLIA SUBSCALE; 6 ITEM HAMILTON MELANCHOLIA SUBSCALE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION ASSESSMENT; DRUG EFFICACY; HUMAN; MELANCHOLIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADULT; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; MALE; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOMETRY; REPRODUCIBILITY;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS;

EID: 84949626004     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2014.10.047     Document Type: Article

References (22)

1. P. Bech, D.K. Kajdasz, and V. Porsdal Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder Psychopharmacology 188 2006 273 280
2. P. Bech, L.F. Gram, E. Dein, O. Jacobsen, J. Vitger, and T.G. Bolwig Quantitative rating of depressive states Acta Psychiatr. Scand. 51 1975 161 170
3. P. Bech, P. Allerup, L.F. Gram, N. Reisby, R. Rosenberg, O. Jacobsen, and A. Nagy The Hamilton depression scale. Evaluation of objectivity using logistic models Acta Psychiatr. Scand. 63 1981 290 299
4. P. Bech, P. Cialdella, M.C. Haugh, M.A. Birkett, A. Hours, J.P. Boissel, and G.D. Tollefson Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression Br. J. Psychiatry 176 2000 421 428
5. P. Bech, P. Tanghoj, H.F. Andersen, and K. Overo Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression Psychopharmacology 163 2002 20 25
6. P. Bech Is the antidepressive effect of second-generation antidepressants a myth? Psychol. Med. 40 2010 181 186
7. P. Bech Clinical Psychometrics 2012 Wiley Blackwell Oxford
8. G. Cumming Understanding the New Statistics: Effect Sizes, Confidance Intervals, and Metaanalysis 2012 Routledge London
9. R. Entsuah, M. Shaffer, and J. Zhang A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects J. Psychiatr. Res. 36 2002 437 448
10. K.N. Fountoulakis, M.T. Samara, and M. Siamouli Burning issues in the meta-analysis of pharmaceutical trials for depression J. Psychopharmacol. 28 2014 106 117
11. R.W. Licht, S. Qvitzau, P. Allerup, and P. Bech Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity? Acta Psychiatr. Scand. 111 2005 144 149
12. K.W. Miskowiak, M. Vinberg, C.J. Harmer, H. Ehrenreich, G.M. Knudsen, J. Macoveanu, A.R. Hansen, O.B. Paulson, H.R. Siebner, and L.V. Kessing Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder Trials 11 2010 (97-6215-11-97), http://www.ncbi.nlm.nih.gov/pubmed/?term=20942940
13. K.W. Miskowiak, M. Vinberg, E.M. Christensen, J.D. Bukh, C.J. Harmer, H. Ehrenreich, and L.V. Kessing Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial Neuropsychopharmacology 39 2014 1399 1408
14. R.J. Mokken Theory and Practice of Scale Analysis 1971 Mouton Berlin
15. I.W. Molenaar, P. Debels, and K. Sijtsna Users Manual MSP, a Program for Mokken Scale Analyses for Polytomous Items (Version 3.0). ProGAMMA 1994 Groeningen The Netherlands
16. H.J. Moller Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale Eur. Arch. Psychiatry Clin. Neurosci. 251 Suppl 2 2001 II13 20
17. S.A. Montgomery The failure of placebo-controlled studies. ECNP Consensus Meeting, September 13, 1997, Vienna. European College of Neuropsychopharmacology Eur. Neuropsychopharmacol. 9 1999 271 276
18. S.D. Ostergaard, P. Bech, M.H. Trivedi, S.R. Wisniewski, A.J. Rush, and M. Fava Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC) J. Affect. Disord. 163 2014 18 24
19. S.D. Ostergaard, B.S. Meyers, A.J. Flint, B.H. Mulsant, E.M. Whyte, C.M. Ulbricht, P. Bech, A.J. Rothschild on behalf of the STOP-PD Study Group Measuring psychotic depression Acta Psychiatr. Scand. 129 2014 211 220
20. S.D. Ostergaard, B.S. Meyers, A.J. Flint, B.H. Mulsant, E.M. Whyte, C.M. Ulbricht, P. Bech, A.J. Rothschild STOP-PD Study Group Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account J. Affect. Disord. 160 2014 68 73
21. M.A. Posternak, D. Young, T. Sheeran, I. Chelminski, C.L. Franklin, and M. Zimmerman Assessing past treatment history: test-retest reliability of the Treatment Response to Antidepressant Questionnaire J. Nerv. Mental Dis. 192 2004 95 102
22. H. Yang, C. Cusin, and M. Fava Is there a placebo problem in antidepressant trials? Curr. Top. Med. Chem. 5 2005 1077 1086